Inhibition of fibroblast growth factors

Breast Cancer Research and Treatment

Volumn 38, Issue 1, 1996, Pages 109-119

  Wellstein, Anton ^a   Czubayko, Frank ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Angiogenesis; Antisense; FGF; Growth factors; Pentosan polysulfate; Ribozymes

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; HEPARIN; HEPARINOID; RIBOZYME; SURAMIN;

ANGIOGENESIS; CONFERENCE PAPER; METASTASIS; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

ANIMALS; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTORS; HEPARAN SULFATE PROTEOGLYCANS; HEPARITIN SULFATE; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDES, ANTISENSE; PENTOSAN SULFURIC POLYESTER; PROTEOGLYCANS;

EID: 0030051838     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01803789     Document Type: Conference Paper

References (68)

1. Folkman J, Klagsbrun M: Angiogenic factors. Science 235:442-447, 1987
2. Cross M, Dexter TM: Growth factors in development, transformation, and tumorigenesis. Cell 64:271-280, 1991
3. Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 64:327-336, 1991
4. Folkman J: How is blood vessel growth regulated in normal and neoplastic tissue? - G.H.A. Clowes Memorial Award Lecture. Cancer Res 46:467-473, 1986
5. Fidler IF, Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79:185-188, 1994
6. Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991
7. Horak ER, Leek R, Klenk N, Lejeunde S, Smith K, Stuart N, Greenall M, Stepniewska K, Harris AL: Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340: 1120-1124, 1992
8. Bosari S, Lee AK, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML: Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 23:755-761, 1992
9. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875-1887, 1992
10. Toi M, Kashitani J, Tominaga T: Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 55:371-374, 1993
11. Macchiarini P, Fontaini G, Jardini MJ, Squartini F, Angeletti CA: Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 340: 145-146, 1992
12. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143: 401-409, 1993
13. Gasparini G, Weidner N, Maluta S, Pozza F, Boracchi P, Mezzetti M, Testolin A, Bevilacqua P: Intratumoral microvessel density and p53 protein: correlation with metastasis in head-and-neck squamous-cell carcinoma. Int J Cancer 55:739-744, 1993
14. Folkman J, Shing Y: Angiogenesis. J Biol Chem 267:10931-10934, 1992
15. Burgess WH, Maciag T: The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem 58:575-606, 1989
16. Mason IJ: The ins and outs of fibroblast growth factors. Cell 78:547-552, 1994
17. Lobb R, Fett J: Purification of two distinct growth factors from bovine neural tissue by heparin affinity chromatography. Biochemistry 23:6295-6299, 1984
18. Maciag T, Tevie M, Friesel R: Heparin binds endothelial cell growth factor, the principal endothelial cell mitogen in bovine brain. Science 225:932-935, 1984
19. Risau W, Gautschi-Sova P, Böhlen P: Endothelial cell growth factors in embryonic and adult chick brain are related to human acidic fibroblast growth factor. EMBO J 7:959-962, 1988
20. Risau W: Developing brain produces an angiogenesis factor. Proc Natl Acad Sci USA 83:3855-3859, 1986
21. Esch F, Baird A, Ling N, Ueno N, Hill F, Denoroy L, Klepper R, Gospodarowicz D, Böhlen P, Guillemin R: Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF. Proc Natl Acad Sci USA 82:6507-6511, 1985
22. Shing Y, Folkman J, Sullivan R, Butterfield C, Murray J, Klagsbrun M: Heparin affinity: Purification of a tumor-derived capillary endothelial cell growth factor. Science 223:1296-1299, 1984
23. Moscatelli D, Presta M, Joseph-Silverstein J, Rifkin DB: Both normal and tumor cells produce basic fibroblast growth factor. J Cell Physiol 129:273-276, 1986
24. Vlodavsky I, Folkman J, Sullivan R, Fridman R, Ishai-Michaeli R, Sasse J, Klagsbrun M: Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci USA 84:2292-2296, 1987
25. Rogelj S, Klagsbrun M, Atzmon R, Kurokawa M, Haimovitz A, Fuks Z, Vlodavsky I: Basic fibroblast growth factor is an extracellular matrix component required for supporting the proliferation of vascular endothelial cells and the differentiation of PC12 cells. J Cell Biol 109:823-831, 1989
26. Saksela O, Moscatelli D, Sommer A, Rifkin DB: Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol 107:743-751, 1988
27. Kiefer MC, Stephans JC, Crawford K, Okino K, Barr PJ: Ligand-affinity cloning and structure of a cell surface heparan sulfate proteoglycan that binds basic fibroblast growth factor. Proc Natl Acad Sci USA 87: 6985-6989, 1990
28. Patterson SL, Grady MS, Bothwell M: Nerve growth factor and a fibroblast growth factor-like neurotrophic activity in cerebrospinal fluid of brain injured human patients. Brain Res 605:43-49, 1993
29. Vlodavsky I, Eldor A, Bar-Ner M, Fridman R, Cohen IR, Klagsbrun M: Heparan sulfate degradation in tumor cell invasion and angiogenesis. Adv Exp Med Biol 233:201-210, 1988
30. Bashkin P, Doctrow S, Klagsbrun M, Svahn CM, Folkman J, Vlodavsky I: Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry 28:1737-1743, 1989
31. Moscatelli D: Basic fibroblast growth factor (bFGF) dissociates rapidly from heparan sulfates but slowly from receptors. Implications for mechanisms of bFGF release from pericellular matrix. J Biol Chem 267: 25803-25809, 1992
32. Vlodavsky I, Bashkin P, Ishai-Michaeli R, Chajek-Shaul T, Bar-Shavit R, Haimovitz-Friedman A, Klagsbrun M, Fuks Z: Sequestration and release of basic fibroblast growth factor. Ann N Y Acad Sci 638:207-220, 1991
33. Wu D, Kan M, Sato GH, Okamoto T, Sato JD: Characterization and molecular cloning of a putative binding protein for heparin-binding growth factors. J Biol Chem 266:16778-16785, 1991
34. Czubayko F, Smith RV, Chung HC, Wellstein A: A secreted binding protein can activate non-secreted FGF in tumors. J Biol Chem 269:28243-28248, 1994
35. Kan M, Wang F, Xu J, Crabb JW, Hou J, McKeehan WL: An essential heparin-binding domain in the fibroblast growth factor receptor kinase. Science 259: 1918-1921, 1993
36. Folkman J, Shing Y: Control of angiogenesis by heparin and other sulfated polysaccharides. Adv Exp Med Biol 313:355-364, 1992
37. Myers CE, La Rocca RV, Cooper MR, Danesi R, Jamis-Dow CA, Stein CA, Linehan WM: Role of suramin in cancer biology and treatment. In: Broder S (ed) Molecular Foundations of Oncology. Williams & Wilkins, Baltimore, 1991, pp 419-431
38. Zugmaier G, Lippman ME, Wellstein A: Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockade by PPS of tumor growth in animals. J Natl Cancer Inst 84:1716-1724, 1992
39. Wellstein A, Zugmaier G, Califano JA III, Kern F, Paik S, Lippman ME: Tumor growth dependent on Kaposi's sarcoma-derived fibroblast growth factor inhibited by pentosan polysulfate. J Natl Cancer Inst 83:716-720, 1991
40. Parker BW, Swain SM, Zugmaier G, Lippman ME, Wellstein A: Detectable inhibition of heparin-binding growth factor activity in sera from patients treated with pentosan polysulfate. J Natl Cancer Inst 85: 1068-1073, 1993
41. Sizmann N, Fang WJ, Chung HC, Rodeck U, Herlyn M, Wellstein A: Pleiotrophin in melanoma metastasis and inhibition by pentosanpolysulfate. Int J Cancer, in press
42. Swain S, Wellstein A, Parker B, Lippman M, Steakley C, DeLap R: Heparin-binding growth factor blockade with pentosan polysulfate. Ann N Y Acad Sci 698: 63-70, 1993
43. Teicher BA, Sotomayor EA, Huang ZD: Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52:6702-6704, 1992
44. Ishihara M, Tyrrell DJ, Stauber GB, Brown S, Cousens LS, Stack RJ: Preparation of affinity-fractionated, heparin-derived oligosaccharides and their effects on selected biological activities mediated by basic fibroblast growth factor. J Biol Chem 268: 4675-4683, 1993
45. Tyrrell DJ, Ishihara M, Rao N, Horne A, Kiefer MC, Stauber GB, Lam LH, Stack RJ: Structure and biological activities of a heparin-derived hexasaccharide with high affinity for basic fibroblast growth factor. J Biol Chem 268:4684-4689, 1993
46. Gospodarowicz D, Ferrara N, Schweigerer L, Neufeld G: Structural characterization and biological functions of fibroblast growth factor. Endocr Rev 8:95-114, 1987
47. Baird A, Klagsbrun M: The fibroblast growth factor family. Cancer Cells 3:239-243, 1991
48. Schreiber AB, Winkler ME, Derynck R: Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science 232: 1250-1253, 1986
49. Weidner KM, Hartmann G, Sachs M, Birchmeier W: Properties and functions of scatter factor/hepatocyte growth factor and its receptor c-Met. Am J Respir Cell Mol Biol 8:229-237, 1993
50. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844, 1993
51. Fang WJ, Hartmann N, Chow D, Riegel AT, Wellstein A: Pleiotrophin stimulates fibroblasts, endothelial and epithelial cells, and is expressed in human cancer. J Biol Chem 267:25889-25897, 1992
52. Toi M, Harris AL, Bicknell R: Interleukin-4 is a potent mitogen for capillary endothelium. Biochem Biophys Res Commun 174:1287-1293, 1991
53. Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O, Alitalo K: Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and epithelial cells. J Biol Chem 269:6271-6274, 1994
54. Myoken Y, Kan M, Sato GH, McKeehan WL, Sato JD: Bifunctional effects of transforming growth factor-beta (TGF-beta) on endothelial cell growth correlate with phenotypes of TGF-beta binding sites. Exp Cell Res 191:299-304, 1990
55. Denekamp J: Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 66:181-196, 1993
56. Hori A, Sasada R, Matsutani E, Naito K, Sakura Y, Fujita T, Kozai Y: Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against basic fibroblast growth factor. Cancer Res 51:6180-6184, 1991
57. Matsuzaki K, Yoshitake Y, Matuo Y, Sasaki H, Nishikawa K: Monoclonal antibodies against heparin-binding growth factor II/basic fibroblast growth factor that block its biological activity: invalidity of the antibodies for tumor angiogenesis. Proc Natl Acad Sci USA 86:9911-9915, 1989
58. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J: Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 86:356-360, 1994
59. Wellstein A: Why monitor angiogenesis factors in the urine of patients? [editorial]. J Natl Cancer Inst 86: 328-329, 1994
60. Wagner RW: Gene inhibition using antisense oligodeoxynucleotides. Nature 372:333-335, 1994
61. Becker D, Meier CB, Herlyn M: Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. EMBO J 8:3685-3691, 1989
62. Cech TR: Nobel lecture. Self-splicing and enzymatic activity of an intervening sequence RNA from Tetrahymena. Biosci Rep 10: 239-261, 1990
63. Symons RH: Small catalytic RNAs. Annu Rev Biochem 61:641-671, 1992
64. Pyle AM: Ribozymes: a distinct class of metalloenzymes. Science 261:709-714, 1993
65. Czubayko F, Riegel AT, Wellstein A: Ribozyme-targeting elucidates a direct role of pleiotrophin in tumor growth. J Biol Chem 269:21358-21363, 1994
66. Uhlenbeck OC: A small catalytic oligoribonucleotide. Nature 328:596-600, 1987
67. Haseloff J, Gerlach WL: Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 334:585-591, 1988
68. Wellstein A, Lupu R, Zugmaier G, Flamm SL, Cheville AL, Delli Bovi P, Basilico C, Lippman ME, Kern FG: Autocrine growth stimulation by secreted Kaposi's fibroblast growth factor but not by endogenous basic fibroblast growth factor. Cell Growth Differ 1:63-71, 1990